Watch NAUT. Know when insiders buy.
One email the day a filing lands. Free.
NAUT
Nautilus Biotechnology, Inc.
0.97
−0.01 −0.62%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
7
FLAG · shorts 7
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $122.9MP/E —DIV YIELD —FCF YIELD -42.19%REV TTM —NET INCOME −$56.5MNET CASH —52W 0.71 – 3.95SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $190K | — | 92.1% | — | −$14.5M | — | -0.11 | −$13.7M | $454K | −$14.2M | Jul 28 |
| Q1 2026 · Mar 31 | — | — | — | — | −$14.7M | — | -0.12 | −$13.1M | $510K | −$13.6M | Apr 28 |
| Q4 2025 · Dec 31derived | — | — | — | — | −$13.8M | — | -0.11 | −$12.4M | $244K | −$12.6M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | — | −$13.6M | — | -0.11 | −$11M | $418K | −$11.5M | Oct 28 |
| Q2 2025 · Jun 30 | $0 | — | — | — | −$15M | — | -0.12 | −$13.3M | $396K | −$13.7M | Jul 28 |
| Q1 2025 · Mar 31 | — | — | — | — | −$16.6M | — | -0.13 | −$13.9M | $219K | −$14.2M | Apr 28 |
| Q4 2024 · Dec 31derived | — | — | — | — | −$17.6M | — | -0.14 | −$14.3M | $254K | −$14.6M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | — | −$16.4M | — | -0.13 | −$13.1M | $709K | −$13.8M | Oct 28 |
| Q2 2024 · Jun 30 | — | — | — | — | −$18M | — | -0.14 | −$15.5M | $512K | −$16M | Jul 31 |
| Q1 2024 · Mar 31 | — | — | — | — | −$18.7M | — | -0.15 | −$16.3M | $647K | −$16.9M | Apr 29 |
| Q4 2023 · Dec 31derived | — | — | — | — | −$17M | — | -0.14 | −$13.9M | $413K | −$14.3M | Feb 27 |
| Q3 2023 · Sep 30 | — | — | — | — | −$15.9M | — | -0.13 | −$11.7M | $874K | −$12.6M | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | — | −$59M | — | -0.47 | −$50.7M | $1.3M | −$52M | — | — |
| FY2024 · to Dec 31 | — | — | — | −$70.8M | — | -0.56 | −$59.1M | $2.1M | −$61.3M | — | — |
| FY2023 · to Dec 31 | — | — | — | −$63.7M | — | -0.51 | −$51.7M | $2.4M | −$54.2M | — | — |
| FY2022 · to Dec 31 | — | — | — | −$57.9M | — | -0.46 | −$45.8M | $2.3M | −$48.1M | — | — |
| FY2021 · to Dec 31 | — | — | — | −$50.3M | — | -0.60 | −$39.2M | $2.3M | −$41.5M | — | — |
| FY2020 · to Dec 31 | — | — | — | −$15.6M | — | -0.54 | −$14M | $921K | −$14.9M | — | — |
Every number comes from Nautilus Biotechnology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.